7-(2,2-dimethyl-propyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine | 676135-98-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 7-(2,2-dimethyl-propyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine
• 英文别名: (1S)-7-(2,2-dimethylpropyl)-1,2,3,4-tetrahydronaphthalen-1-amine
• CAS: 676135-98-1
• 化学式: C₁₅H₂₃N
• 分子量: 217.354
• InChiKey: MXPWUMGRPOLLDD-AWEZNQCLSA-N

物化性质

• 沸点：
  319.9±21.0 °C(Predicted)
• 密度：
  0.960±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-(2,2-dimethyl-propyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine 在 盐酸 、 1-羟基苯并三唑 、 N-甲基吗啉氧化物 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 异丙醇 为溶剂， 生成 N-(1S,2R)-{1-(3,5-difluoro-benzyl)-3-[(1S)-7-(2,2-dimethylpropyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamino]-2-hydroxypropyl}-acetamide
  参考文献：
  名称：

  Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

  摘要：

  The structure structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1' region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimization of the P2' substituent of chromane-HEA(s) with polar substituents provided improvements in the compound's in vitro permeability. Significant potency gains were observed with small aliphatic substituents such as methyl, n-propyl, and cyclopropyl when placed at the C-2 position of the chromane. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.006
• 作为产物：
  描述：

  (R)-(-)-1,2,3,4-四氢-1-萘酚 在 lithium aluminium tetrahydride 、 叠氮磷酸二苯酯 、 Pd(1,1-bis(diphenylphosphino)ferrocene)₂Cl₂ 、 碘 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 mercury(II) oxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 生成 7-(2,2-dimethyl-propyl)-1,2,3,4-tetrahydro-naphthalen-1-ylamine
  参考文献：
  名称：

  Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

  摘要：

  The structure structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1' region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimization of the P2' substituent of chromane-HEA(s) with polar substituents provided improvements in the compound's in vitro permeability. Significant potency gains were observed with small aliphatic substituents such as methyl, n-propyl, and cyclopropyl when placed at the C-2 position of the chromane. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.006

文献信息

• Acetyl 2-hydroxy-1, 3-diaminoalkanes
  申请人：John Varghese

  公开号：US20070293483A1

  公开（公告）日：2007-12-20

  Disclosed are compounds of the formula: where variables Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明涉及以下式子的化合物：其中变量Z、X、R15、R2、R3和Rc在此定义。本发明揭示的化合物是β-分泌酶酶的抑制剂，因此在治疗老年痴呆症和其他以A beta肽在哺乳动物中沉积为特征的疾病中有用。
• ACETYL 2-HYDROXY-1,3-DIAMINOALKANES
  申请人：John Varghese

  公开号：US20100145056A1

  公开（公告）日：2010-06-10

  Disclosed are compounds of the formula: where variables Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  公开了以下式子的化合物：其中变量Z，X，R15，R2，R3和R4在此处定义。本文所披露的化合物是β-分泌酶酶的抑制剂，因此在治疗阿尔茨海默病和其他以A beta肽在哺乳动物中沉积为特征的疾病中有用。
• [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT DE L'AMYLOSE METTANT EN OEUVRE DES INHIBITEURS DE LA PROTEASE A BASE D'ASPARTYLE BICYCLIQUE
  申请人：ELAN PHARM INC

  公开号：WO2005087714A3

  公开（公告）日：2005-12-15
• [EN] 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES<br/>[FR] 1,3-DIAMINOPROPANES A SUBSTITUTION 2-AMINO- ET 2-THIO-
  申请人：ELAN PHARM INC

  公开号：WO2005095326A3

  公开（公告）日：2005-11-10
• SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS
  申请人：JOHN Varghese

  公开号：US20090270367A1

  公开（公告）日：2009-10-29

  The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.